A Phase I/II study of thiotepa, ifosphamide, etoposide and rituximab for the treatment of relapsed or refractory primary central nervous system lymphoma

Trial Profile

A Phase I/II study of thiotepa, ifosphamide, etoposide and rituximab for the treatment of relapsed or refractory primary central nervous system lymphoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Sep 2017

At a glance

  • Drugs Thiotepa (Primary) ; Etoposide; Ifosfamide; Rituximab
  • Indications CNS cancer; Diffuse large B cell lymphoma
  • Focus Adverse reactions
  • Acronyms TIER
  • Most Recent Events

    • 14 Jul 2015 Accrual to date is 2% as reported by United Kingdom Clinical Research Network record.
    • 13 Feb 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top